CREBBP mutations in relapsed acute lymphoblastic leukaemia (original) (raw)

Nature volume 471, pages 235–239 (2011)Cite this article

Subjects

Abstract

Relapsed acute lymphoblastic leukaemia (ALL) is a leading cause of death due to disease in young people, but the biological determinants of treatment failure remain poorly understood. Recent genome-wide profiling of structural DNA alterations in ALL have identified multiple submicroscopic somatic mutations targeting key cellular pathways1,2, and have demonstrated substantial evolution in genetic alterations from diagnosis to relapse3. However, DNA sequence mutations in ALL have not been analysed in detail. To identify novel mutations in relapsed ALL, we resequenced 300 genes in matched diagnosis and relapse samples from 23 patients with ALL. This identified 52 somatic non-synonymous mutations in 32 genes, many of which were novel, including the transcriptional coactivators CREBBP and NCOR1, the transcription factors ERG, SPI1, TCF4 and TCF7L2, components of the Ras signalling pathway, histone genes, genes involved in histone modification (CREBBP and CTCF), and genes previously shown1,2 to be targets of recurring DNA copy number alteration in ALL. Analysis of an extended cohort of 71 diagnosis–relapse cases and 270 acute leukaemia cases that did not relapse found that 18.3% of relapse cases had sequence or deletion mutations of CREBBP, which encodes the transcriptional coactivator and histone acetyltransferase CREB-binding protein (CREBBP, also known as CBP)4. The mutations were either present at diagnosis or acquired at relapse, and resulted in truncated alleles or deleterious substitutions in conserved residues of the histone acetyltransferase domain. Functionally, the mutations impaired histone acetylation and transcriptional regulation of CREBBP targets, including glucocorticoid responsive genes. Several mutations acquired at relapse were detected in subclones at diagnosis, suggesting that the mutations may confer resistance to therapy. These results extend the landscape of genetic alterations in leukaemia, and identify mutations targeting transcriptional and epigenetic regulation as a mechanism of resistance in ALL.

This is a preview of subscription content, access via your institution

Access options

Subscribe to this journal

Receive 51 print issues and online access

$199.00 per year

only $3.90 per issue

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Additional access options:

Similar content being viewed by others

References

  1. Mullighan, C. G. et al. Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. Nature 446, 758–764 (2007)
    Article ADS CAS Google Scholar
  2. Kuiper, R. P. et al. High-resolution genomic profiling of childhood ALL reveals novel recurrent genetic lesions affecting pathways involved in lymphocyte differentiation and cell cycle progression. Leukemia 21, 1258–1266 (2007)
    Article CAS Google Scholar
  3. Mullighan, C. G. et al. Genomic analysis of the clonal origins of relapsed acute lymphoblastic leukemia. Science 322, 1377–1380 (2008)
    Article ADS CAS Google Scholar
  4. Goodman, R. H. & Smolik, S. CBP/p300 in cell growth, transformation, and development. Genes Dev. 14, 1553–1577 (2000)
    CAS PubMed Google Scholar
  5. Pui, C. H., Robison, L. L. & Look, A. T. Acute lymphoblastic leukaemia. Lancet 371, 1030–1043 (2008)
    Article CAS Google Scholar
  6. Harrison, C. J. Cytogenetics of paediatric and adolescent acute lymphoblastic leukaemia. Br. J. Haematol. 144, 147–156 (2009)
    Article Google Scholar
  7. Mullighan, C. G. et al. Deletion of IKZF1 and prognosis in Acute Lymphoblastic Leukemia. N. Engl. J. Med. 360, 470–480 (2009)
    Article CAS Google Scholar
  8. Kuiper, R. P. et al. IKZF1 deletions predict relapse in uniformly treated pediatric precursor B-ALL. Leukemia 24, 1258–1264 (2010)
    Article CAS Google Scholar
  9. Yang, J. J. et al. Genome-wide copy number profiling reveals molecular evolution from diagnosis to relapse in childhood acute lymphoblastic leukemia. Blood 112, 4178–4183 (2008)
    Article CAS Google Scholar
  10. Vo, N. & Goodman, R. H. CREB-binding protein and p300 in transcriptional regulation. J. Biol. Chem. 276, 13505–13508 (2001)
    Article CAS Google Scholar
  11. Blobel, G. A. CREB-binding protein and p300: molecular integrators of hematopoietic transcription. Blood 95, 745–755 (2000)
    CAS PubMed Google Scholar
  12. Yang, X. J. The diverse superfamily of lysine acetyltransferases and their roles in leukemia and other diseases. Nucleic Acids Res. 32, 959–976 (2004)
    Article CAS Google Scholar
  13. Schorry, E. K. et al. Genotype-phenotype correlations in Rubinstein-Taybi syndrome. Am. J. Med. Genet. A. 146A, 2512–2519 (2008)
    Article CAS Google Scholar
  14. Miller, R. W. & Rubinstein, J. H. Tumors in Rubinstein-Taybi syndrome. Am. J. Med. Genet. 56, 112–115 (1995)
    Article CAS Google Scholar
  15. Kung, A. L. et al. Gene dose-dependent control of hematopoiesis and hematologic tumor suppression by CBP. Genes Dev. 14, 272–277 (2000)
    CAS PubMed PubMed Central Google Scholar
  16. Iyer, N. G., Ozdag, H. & Caldas, C. p300/CBP and cancer. Oncogene 23, 4225–4231 (2004)
    Article CAS Google Scholar
  17. Kishimoto, M. et al. Mutations and deletions of the CBP gene in human lung cancer. Clin. Cancer Res. 11, 512–519 (2005)
    CAS PubMed Google Scholar
  18. Shigeno, K. et al. Disease-related potential of mutations in transcriptional cofactors CREB-binding protein and p300 in leukemias. Cancer Lett. 213, 11–20 (2004)
    Article CAS Google Scholar
  19. Radtke, I. et al. Genomic analysis reveals few genetic alterations in pediatric acute myeloid leukemia. Proc. Natl Acad. Sci. USA 106, 12944–12949 (2009)
    Article ADS CAS Google Scholar
  20. Mullighan, C. G. et al. BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros. Nature 453, 110–114 (2008)
    Article ADS CAS Google Scholar
  21. Mullighan, C. G. et al. Rearrangement of CRLF2 in B-progenitor- and Down syndrome-associated acute lymphoblastic leukemia. Nature Genet. 41, 1243–1246 (2009)
    Article CAS Google Scholar
  22. Liu, X. et al. The structural basis of protein acetylation by the p300/CBP transcriptional coactivator. Nature 451, 846–850 (2008)
    Article ADS CAS Google Scholar
  23. Kang-Decker, N. et al. Loss of CBP causes T cell lymphomagenesis in synergy with p27Kip1 insufficiency. Cancer Cell 5, 177–189 (2004)
    Article CAS Google Scholar
  24. Kasper, L. H. et al. Conditional knockout mice reveal distinct functions for the global transcriptional coactivators CBP and p300 in T-cell development. Mol. Cell. Biol. 26, 789–809 (2006)
    Article CAS Google Scholar
  25. Kasper, L. H. et al. CBP/p300 double null cells reveal effect of coactivator level and diversity on CREB transactivation. EMBO J. 29, 3660–3672 (2010)
    Article CAS Google Scholar
  26. Dordelmann, M. et al. Prednisone response is the strongest predictor of treatment outcome in infant acute lymphoblastic leukemia. Blood 94, 1209–1217 (1999)
    CAS PubMed Google Scholar
  27. Pasqualucci, L. et al. Inactivating mutations of acetyltransferase genes in B-cell lymphoma. Nature 10.1038/nature09730 (this issue)
  28. Bolden, J. E., Peart, M. J. & Johnstone, R. W. Anticancer activities of histone deacetylase inhibitors. Nature Rev. Drug Discov. 5, 769–784 (2006)
    Article CAS Google Scholar
  29. Tsapis, M. et al. HDAC inhibitors induce apoptosis in glucocorticoid-resistant acute lymphatic leukemia cells despite a switch from the extrinsic to the intrinsic death pathway. Int. J. Biochem. Cell Biol. 39, 1500–1509 (2007)
    Article CAS Google Scholar
  30. Bordoli, L. et al. Functional analysis of the p300 acetyltransferase domain: the PHD finger of p300 but not of CBP is dispensable for enzymatic activity. Nucleic Acids Res. 29, 4462–4471 (2001)
    Article CAS Google Scholar
  31. Drexler, H. G. The Leukemia-Lymphoma Cell Line Facts Book 1st edn (Academic Press, 2001)
    Google Scholar
  32. Manabe, A. et al. Interleukin-4 induces programmed cell death (apoptosis) in cases of high-risk acute lymphoblastic leukemia. Blood 83, 1731–1737 (1994)
    CAS PubMed Google Scholar
  33. Sherry, S. T. et al. dbSNP: the NCBI database of genetic variation. Nucleic Acids Res. 29, 308–311 (2001)
    Article CAS Google Scholar
  34. Ewing, B., Hillier, L., Wendl, M. C. & Green, P. Base-calling of automated sequencer traces using phred. I. Accuracy assessment. Genome Res. 8, 175–185 (1998)
    Article CAS Google Scholar
  35. Ewing, B. & Green, P. Base-calling of automated sequencer traces using phred. II. Error probabilities. Genome Res. 8, 186–194 (1998)
    Article CAS Google Scholar
  36. Zhang, J. et al. SNPdetector: a software tool for sensitive and accurate SNP detection. PLOS Comput. Biol. 1, e53 (2005)
    Article ADS Google Scholar
  37. Zhang, J. et al. Systematic analysis of genetic alterations in tumors using Cancer Genome WorkBench (CGWB). Genome Res. 17, 1111–1117 (2007)
    Article CAS Google Scholar
  38. Zhang, J., Rowe, W. L., Struewing, J. P. & Buetow, K. H. HapScope: a software system for automated and visual analysis of functionally annotated haplotypes. Nucleic Acids Res. 30, 5213–5221 (2002)
    Article CAS Google Scholar
  39. Bamford, S. et al. The COSMIC (Catalogue of Somatic Mutations in Cancer) database and website. Br. J. Cancer 91, 355–358 (2004)
    Article CAS Google Scholar
  40. Gordon, D., Albajian, C. & Green, P. Consed: a graphical tool for sequence finishing. Genome Res. 8, 195–202 (1998)
    Article CAS Google Scholar
  41. Andrews, N. C. & Faller, D. V. A rapid micropreparation technique for extraction of DNA-binding proteins from limiting numbers of mammalian cells. Nucleic Acids Res. 19, 2499 (1991)
    Article CAS Google Scholar
  42. Berman, H., Henrick, K. & Nakamura, H. Announcing the worldwide Protein Data Bank. Nature Struct. Biol. 10, 980 (2003)
    Article CAS Google Scholar
  43. DeLano, W. L. The PyMOL Molecular Graphics System. 〈http://www.pymol.org〉 (2002)

Download references

Acknowledgements

We thank T. Jeevan, S. Orwick and A. Gibson for technical assistance, B. Schulman for assistance with structural modelling, and B. Woolf and J. Hartigan of Beckman Coulter Genomics for assistance with sequencing. We thank the Tissue Resources Facility of St Jude Children’s Research Hospital for providing samples, and the following St Jude core facilities: Vector Development and Production, Flow Cytometry and Cell Sorting, Cell and Tissue Imaging, the Animal Resource Center, and the DNA sequencing and Macromolecular Synthesis laboratories of the Hartwell Center for Bioinformatics and Biotechnology. This study was supported by ALSAC of St Jude and Cancer Center support grant P30 CA021765, and grant number DE018183 (P.K.B.). C.G.M. is a Pew Scholar in the Biomedical Sciences.

Author information

Author notes

  1. Charles G. Mullighan and Jinghui Zhang: These authors contributed equally to this work.

Authors and Affiliations

  1. Department of Pathology, St Jude Children’s Research Hospital, Memphis, 38105, Tennessee, USA
    Charles G. Mullighan, Debbie Payne-Turner, Letha A. Phillips, Sue L. Heatley, Linda Holmfeldt, J. Racquel Collins-Underwood & James R. Downing
  2. Department of Computational Biology, St Jude Children’s Research Hospital, Memphis, 38105, Tennessee, USA
    Jinghui Zhang
  3. Department of Biochemistry, St Jude Children’s Research Hospital, Memphis, 38105, Tennessee, USA
    Lawryn H. Kasper, Stephanie Lerach & Paul K. Brindle
  4. The Hartwell Center for Bioinformatics and Biotechnology, St Jude Children’s Research Hospital, Memphis, 38105, Tennessee, USA
    Jing Ma
  5. National Cancer Institute Center for Bioinformatics, National Cancer Institute, Rockville, 20892, Maryland, USA
    Kenneth H. Buetow
  6. Laboratory of Population Genetics, National Cancer Institute, National Institutes of Health, Bethesda, 20892, Maryland, USA
    Kenneth H. Buetow
  7. Department of Oncology, St Jude Children’s Research Hospital, Memphis, 38105, Tennessee, USA
    Ching-Hon Pui
  8. Department of Pharmaceutical Sciences, St Jude Children’s Research Hospital, Memphis, 38105, Tennessee, USA
    Sharyn D. Baker

Authors

  1. Charles G. Mullighan
    You can also search for this author inPubMed Google Scholar
  2. Jinghui Zhang
    You can also search for this author inPubMed Google Scholar
  3. Lawryn H. Kasper
    You can also search for this author inPubMed Google Scholar
  4. Stephanie Lerach
    You can also search for this author inPubMed Google Scholar
  5. Debbie Payne-Turner
    You can also search for this author inPubMed Google Scholar
  6. Letha A. Phillips
    You can also search for this author inPubMed Google Scholar
  7. Sue L. Heatley
    You can also search for this author inPubMed Google Scholar
  8. Linda Holmfeldt
    You can also search for this author inPubMed Google Scholar
  9. J. Racquel Collins-Underwood
    You can also search for this author inPubMed Google Scholar
  10. Jing Ma
    You can also search for this author inPubMed Google Scholar
  11. Kenneth H. Buetow
    You can also search for this author inPubMed Google Scholar
  12. Ching-Hon Pui
    You can also search for this author inPubMed Google Scholar
  13. Sharyn D. Baker
    You can also search for this author inPubMed Google Scholar
  14. Paul K. Brindle
    You can also search for this author inPubMed Google Scholar
  15. James R. Downing
    You can also search for this author inPubMed Google Scholar

Contributions

C.G.M., P.K.B. and J.R.D. designed the study. S.L.H., L.H., C.G.M., L.A.P. and D.P.-T. performed PCR and sequencing. J.Z. and K.H.B. analysed sequence data. L.H.K. and S.L. performed in vitro assays of the functional activity of Crebbp mutants. J.M. analysed genomic data. S.L.H. and J.R.C.-U. performed cell line assays. S.D.B. designed and performed leukaemia cell line drug responsiveness assays. C.-H.P. provided samples and clinical data. C.G.M. wrote the manuscript. All authors reviewed the manuscript.

Corresponding author

Correspondence toCharles G. Mullighan.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Supplementary information

Supplementary Information

The file contains Supplementary Results, Supplementary Tables 1-7, Supplementary Figures 1-12 with legends and additional references. (PDF 1392 kb)

PowerPoint slides

Rights and permissions

About this article

Cite this article

Mullighan, C., Zhang, J., Kasper, L. et al. CREBBP mutations in relapsed acute lymphoblastic leukaemia.Nature 471, 235–239 (2011). https://doi.org/10.1038/nature09727

Download citation

This article is cited by

Editorial Summary

CREBBP and EP300 mutations in B-cell lymphoma

In three different subtypes of B-cell lymphomas, two papers report frequent somatic mutations in the genes CREBBP and EP300, which are present in primary tumours or acquired at relapse. These genes encode related acetyltransferases that mainly function to regulate gene expression by acetylating histones and other transcriptional regulators. The mutations disrupt these activities and thus alter chromatin regulation of gene expression, as well as proliferation and potentially the response to anticancer drugs. These studies may provide a rationale for the use of histone deacetylase inhibitors in certain B-cell lymphomas.